Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Is there any upper limit of volume or shape of a prostate gland which would be a red flag to cytoreduce prior to treatment?
What is the upper limit of size you would consider offering a patient a five fraction regimen?
Answer from: Radiation Oncologist at Community Practice
Astro/aua consensus guidelines based on published data limits to 100cc or less
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This consensus statement is for SBRT
860
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
No.
Sign in or Register to read more
4362
4375
Related Questions
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
How do you approach rising PSA following radical prostatectomy and early salvage radiation therapy?
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Given the PATRIOT trial and hypo-FLAME 2.0, do you consider once-a-week prostate SBRT instead of every other day?
What adjuvant treatment would you offer a patient who underwent cystoprostatectomy for a muscle invasive bladder cancer and discovered to also have prostate cancer?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
In light of the recent data indicating increased late grade 3 to 5 toxicities (LTOX3) after hypofractionated salvage radiation therapy, will you continue to offer these regimes to patients?
For a patient with a rising PSA after prostatectomy with seminal vesicles being negative for disease at surgery, do you ever treat the prostate bed and seminal vesicle bed with different doses in an SIB plan?
This consensus statement is for SBRT